Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. Jude Starts Pivotal Depression Trial For Deep Brain Stimulator

This article was originally published in The Gray Sheet

Executive Summary

St. Jude Medical officially entered the race Feb. 7 to successfully market an implantable neurostimulator for depression, announcing FDA clearance for a pivotal trial testing its Libra deep brain stimulation device for the indication

You may also be interested in...



St. Jude/ANS Spotlights Trials Of Three Neurostim Indications

St. Jude Medical is touting neuromodulation as the next big new market opportunity for the company

St. Jude/ANS Spotlights Trials Of Three Neurostim Indications

St. Jude Medical is touting neuromodulation as the next big new market opportunity for the company

Northstar Neuroscience Says It Has The Cash To Overcome EVEREST Setback

Northstar Neuroscience says it has enough cash reserves to continue developing its cortical stimulation technology for tinnitus and depression, despite the disappointing results of the first pivotal trial for a stroke indication

Related Content

UsernamePublicRestriction

Register

LL1134478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel